Skip to main content
Erschienen in: Tumor Biology 7/2016

21.01.2016 | Original Article

Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy

verfasst von: Lukáš Krbal, Veronika Hanušová, Jiří Soukup, Stanislav John, Petra Matoušková, Aleš Ryška

Erschienen in: Tumor Biology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer has been a leading cause of cancer-related morbidity and mortality. For the research and individualization of therapy, primary cell lines of the colorectal cancer appear to be still an invaluable tool. We evaluated the differences in metastatic potential between four isolated primary colon cancer cells and cells derived from their lymph node metastasis. These results were compared with correspond immortalized cells—SW480 and SW620, respectively. The ability to migrate was tested using real-time measurement in xCELLigence system. Expressions of molecules involved in adhesion and invasion processes were examined using RT-PCR and western blot analysis. Furthermore, impact of cytotoxic effect of selected chemotherapeutics (irinotecan, oxaliplatin) and biological therapy (bevacizumab, cetuximab, panitumumab) was assessed by the WST assay. As expected, cell lines derived from lymph node migrated more aggressively and higher expression of adhesion molecules ICAM-1, EpCAM, and N-cadherin was detected. The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a. The most pronounced cytotoxic effect has been recorded with oxaliplatin and irinotecan (IC50 = 48.23 resp. 0.11 μg/ml), especially in cells originating from lymph node metastases. In total, comparison of isolated cell lines and immortalized cell lines has shown many similarities, as well as several differences. Adhesion/invasion molecules and several miRNAs, which play an important role in tumor development and the invasive and migratory behavior, could be a useful therapeutic target in malignant colorectal cancer.
Literatur
3.
Zurück zum Zitat Tang R, Wang JY, Chen JS, Chang-Chien CR, Tang S, Lin SE, et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995;180(6):705–12.PubMed Tang R, Wang JY, Chen JS, Chang-Chien CR, Tang S, Lin SE, et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995;180(6):705–12.PubMed
5.
Zurück zum Zitat Kaneko I, Tanaka S, Oka S, Kawamura T, Hiyama T, Ito M, et al. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum. 2007;50(1):13–21. doi:10.1007/s10350-006-0745-5.CrossRefPubMed Kaneko I, Tanaka S, Oka S, Kawamura T, Hiyama T, Ito M, et al. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum. 2007;50(1):13–21. doi:10.​1007/​s10350-006-0745-5.CrossRefPubMed
9.
Zurück zum Zitat Palomares T, Alonso-Varona A, García-Alonso I, Portugal V. New strategies to enhance the efficacy of surgical treatment for colorectal liver metastasis. Colorectal Cancer - Surgery, Diagnostics and Treatment. 2014. Palomares T, Alonso-Varona A, García-Alonso I, Portugal V. New strategies to enhance the efficacy of surgical treatment for colorectal liver metastasis. Colorectal Cancer - Surgery, Diagnostics and Treatment. 2014.
10.
Zurück zum Zitat Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR. The prognostic impact of protein expression of E-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. 2010. doi:10.1155/2010/616023.PubMedPubMedCentral Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR. The prognostic impact of protein expression of E-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. 2010. doi:10.​1155/​2010/​616023.PubMedPubMedCentral
11.
Zurück zum Zitat Ikeguchi M, Taniguchi T, Makino M, Kaibara N. Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol. 2000;35(8):839–46.CrossRefPubMed Ikeguchi M, Taniguchi T, Makino M, Kaibara N. Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol. 2000;35(8):839–46.CrossRefPubMed
12.
Zurück zum Zitat Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology. 2007;50(4):453–64. doi:10.1111/j.1365-2559.2007.02620.x.CrossRefPubMed Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology. 2007;50(4):453–64. doi:10.​1111/​j.​1365-2559.​2007.​02620.​x.CrossRefPubMed
13.
Zurück zum Zitat Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol. 2006;93(2):151–60. doi:10.1002/jso.20413.CrossRefPubMed Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol. 2006;93(2):151–60. doi:10.​1002/​jso.​20413.CrossRefPubMed
14.
Zurück zum Zitat Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707–15.PubMedPubMedCentral Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707–15.PubMedPubMedCentral
15.
Zurück zum Zitat Zhuo HQ, Jiang KW, Dong LY, Zhu Y, Lu L, Lu Y, et al. Overexpression of N-cadherin is correlated with metastasis and worse survival in colorectal cancer patients. Chin Sci Bull. 2013;58(28-29):3529–34. doi:10.1007/s11434-013-5813-3.CrossRef Zhuo HQ, Jiang KW, Dong LY, Zhu Y, Lu L, Lu Y, et al. Overexpression of N-cadherin is correlated with metastasis and worse survival in colorectal cancer patients. Chin Sci Bull. 2013;58(28-29):3529–34. doi:10.​1007/​s11434-013-5813-3.CrossRef
16.
Zurück zum Zitat Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002;1(6):415–26. doi:10.1038/nrd819.CrossRefPubMed Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: novel clinical approaches. Nat Rev Drug Discov. 2002;1(6):415–26. doi:10.​1038/​nrd819.CrossRefPubMed
17.
Zurück zum Zitat Moutasim K, Nystrom M, Thomas G (2011) Cell migration and invasion assays. In: Cree IA (ed) Cancer cell culture, vol 731. Methods in molecular biology. Humana Press, pp 333-343. doi:10.1007/978-1-61779-080-5_27 Moutasim K, Nystrom M, Thomas G (2011) Cell migration and invasion assays. In: Cree IA (ed) Cancer cell culture, vol 731. Methods in molecular biology. Humana Press, pp 333-343. doi:10.​1007/​978-1-61779-080-5_​27
18.
20.
Zurück zum Zitat Ljung BM, Mayall B, Lottich C, Boyer C, Sylvester SS, Leight GS, et al. Cell dissociation techniques in human breast cancer—variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat. 1989;13(2):153–9.CrossRefPubMed Ljung BM, Mayall B, Lottich C, Boyer C, Sylvester SS, Leight GS, et al. Cell dissociation techniques in human breast cancer—variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat. 1989;13(2):153–9.CrossRefPubMed
21.
Zurück zum Zitat Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013;31(6):347–54.CrossRefPubMedPubMedCentral Mitra A, Mishra L, Li S. Technologies for deriving primary tumor cells for use in personalized cancer therapy. Trends Biotechnol. 2013;31(6):347–54.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8(1):102.CrossRefPubMedPubMedCentral Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8(1):102.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320–6. doi:10.3892/or.2013.2475.PubMed Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320–6. doi:10.​3892/​or.​2013.​2475.PubMed
26.
Zurück zum Zitat Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta. 2015;1856(1):28–38. doi:10.1016/j.bbcan.2015.04.001.PubMed Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta. 2015;1856(1):28–38. doi:10.​1016/​j.​bbcan.​2015.​04.​001.PubMed
27.
28.
Zurück zum Zitat Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, et al. The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori. 2009;95(3):343–7.PubMed Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, et al. The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori. 2009;95(3):343–7.PubMed
30.
Zurück zum Zitat Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res Off J Ame Assoc Cancer Res. 2004;10(12 Pt 1):4125–33. doi:10.1158/1078-0432.CCR-0578-03.CrossRef Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res Off J Ame Assoc Cancer Res. 2004;10(12 Pt 1):4125–33. doi:10.​1158/​1078-0432.​CCR-0578-03.CrossRef
31.
Zurück zum Zitat Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.PubMed Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.PubMed
33.
Zurück zum Zitat Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, et al. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep. 2002;9(3):511–4.PubMed Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, et al. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep. 2002;9(3):511–4.PubMed
34.
Zurück zum Zitat Kelly CP, O'Keane JC, Orellana J, Schroy 3rd PC, Yang S, LaMont JT, et al. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. The American journal of physiology. 1992;263(6 Pt 1):G864–70.PubMed Kelly CP, O'Keane JC, Orellana J, Schroy 3rd PC, Yang S, LaMont JT, et al. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. The American journal of physiology. 1992;263(6 Pt 1):G864–70.PubMed
35.
Zurück zum Zitat Zhang YY, Chen B, Ding YQ. Metastasis-associated factors facilitating the progression of colorectal cancer. Asian Pac J Cancer Prev: APJCP. 2012;13(6):2437–44.CrossRefPubMed Zhang YY, Chen B, Ding YQ. Metastasis-associated factors facilitating the progression of colorectal cancer. Asian Pac J Cancer Prev: APJCP. 2012;13(6):2437–44.CrossRefPubMed
36.
Zurück zum Zitat Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):101–17.CrossRefPubMed Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):101–17.CrossRefPubMed
37.
Zurück zum Zitat Kheirelseid EAH, Miller N, Chang KH, Nugent M, Kerin MJ. Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol. 2013;4(2):144–57.PubMedPubMedCentral Kheirelseid EAH, Miller N, Chang KH, Nugent M, Kerin MJ. Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol. 2013;4(2):144–57.PubMedPubMedCentral
38.
Zurück zum Zitat Triulzi T, Tagliabue E, Casalini P, Iorio MV. microRNA: New Players in Metastatic Process. Oncogene and Cancer - From Bench to Clinic. 2013. Triulzi T, Tagliabue E, Casalini P, Iorio MV. microRNA: New Players in Metastatic Process. Oncogene and Cancer - From Bench to Clinic. 2013.
40.
Zurück zum Zitat Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–83. doi:10.1016/S1470-2045(07)70245-0.CrossRefPubMed Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–83. doi:10.​1016/​S1470-2045(07)70245-0.CrossRefPubMed
41.
Zurück zum Zitat Dahan L, Sadok A, Formento JL, Seitz J, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–20.CrossRefPubMedPubMedCentral Dahan L, Sadok A, Formento JL, Seitz J, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–20.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol: Off J Ame Soc Clin Oncol. 2007;25(23):3456–61. doi:10.1200/JCO.2007.11.2144.CrossRef Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol: Off J Ame Soc Clin Oncol. 2007;25(23):3456–61. doi:10.​1200/​JCO.​2007.​11.​2144.CrossRef
43.
Zurück zum Zitat Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(19):3117–25.CrossRef Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(19):3117–25.CrossRef
44.
Zurück zum Zitat Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39(1):112–9.CrossRefPubMed Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39(1):112–9.CrossRefPubMed
45.
Zurück zum Zitat Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol Pharm Bull. 2014;37(1):67–73. doi:10.1248/bpb.b13-00574.CrossRefPubMed Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol Pharm Bull. 2014;37(1):67–73. doi:10.​1248/​bpb.​b13-00574.CrossRefPubMed
47.
Zurück zum Zitat Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif. 2014;47(5):435–47. doi:10.1111/cpr.12125.CrossRefPubMed Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif. 2014;47(5):435–47. doi:10.​1111/​cpr.​12125.CrossRefPubMed
Metadaten
Titel
Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy
verfasst von
Lukáš Krbal
Veronika Hanušová
Jiří Soukup
Stanislav John
Petra Matoušková
Aleš Ryška
Publikationsdatum
21.01.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4839-y

Weitere Artikel der Ausgabe 7/2016

Tumor Biology 7/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.